Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.

Motzer, Robert J; Escudier, Bernard; Powles, Thomas; Scheffold, Christian; Choueiri, Toni K.
Br J Cancer; 118(9): 1176-1178, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29576624